Getinge up 10% today. Furhter upside on the way

I have written here about Getinge before. Today, as predicted, Getinge announced that FDA is concluding its investigation with only symbolic fine. As a result the share is 10% up before the call.

I believe there is another 10% on the table. The company announced that they will host an investor day to inform investors on the restructuring and costs saving plan. Both the announcement and the event itself will drive the share price up further. Below is Reuters article:

UPDATE 1-Getinge shares shoot up as U.S. regulatory woes clear

    * Getinge sees FDA agreement soon, to cost about 500 mln SEK 
    * Sees improved growth in 2015 
    * Q4 adjusted EBITA 1.99 bln SEK vs poll forecast 2.11 bln. 
 
 (Adds detail, background, shares) 
    STOCKHOLM, Jan 28 (Reuters) - Swedish medical technology 
firm Getinge <GETIb.ST> said regulatory troubles in its biggest 
market looked set to end, sending its shares sharply higher as 
it posted fourth-quarter core profit below expectations. 
    Inspections by the U.S. Food and Drug Administration had 
forced it to spend heavily to improve manufacturing quality 
controls in its biggest business area and led to a cloudy short 
term profit outlook in the face of potential fines and 
restrictions on what products it can sell in its biggest market. 
    Getinge said on Wednesday it expected to reach an agreement 
with the FDA soon which would shave about 500 million Swedish 
crowns ($61 million) off its operating profit this year but did 
not provide further details of the deal. 
    Shares in Getinge rose by 10 percent to 205.50 crowns by 
1257 GMT, on track for their biggest one-day gain in six years, 
as the regulatory uncertainty looked set to clear. 
    That uncertainty had weighed on its shares, which had fallen 
15 percent since the start of 2014 by Tuesday's close against a 
rise of 31 percent in the STOXX Europe Healthcare index <.SXDP> 
    "This is mainly about risk reduction and the fact that they 
can already outline the extra costs for the FDA process," said 
Swedbank analyst Johan Unnerus.  
    Earnings before interest, taxes, amortisation and 
restructuring costs fell to 1.99 billion Swedish crowns ($243 
million) in the fourth quarter from a year-earlier 2.06 billion. 
The mean forecast in a Reuters poll of analysts was for 2.11 
billion. [ID:nL6N0V11LR] 
    Getinge said it expected better growth in 2015 after posting 
like-for-like sales growth of 0.6 percent in 2014, and that the 
potential for improving profitability in the medium term 
remained favourable. 
($1 = 8.1757 Swedish crowns)